ABCA7 (ATP-Binding Cassette Transporter A7)

Pathway Diagram

flowchart TD
    ABCA7["ABCA7"]
    style ABCA7 fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0
    Cholesterol_Transport["Cholesterol Transport"]
    ABCA7 -->|"modulates"| Cholesterol_Transport
    Lipid_Processing["Lipid Processing"]
    ABCA7 -->|"modulates"| Lipid_Processing
    APOE["APOE"]
    ABCA7 -->|"associated with"| APOE
    Alzheimer["Alzheimer"]
    ABCA7 -->|"associated with"| Alzheimer
    ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"]
    ABCA7 -->|"associated with"| ALZHEIMER_S_DISEASE
    TREM2["TREM2"]
    ABCA7 -->|"associated with"| TREM2
    ALZHEIMER["ALZHEIMER"]
    ABCA7 -->|"associated with"| ALZHEIMER
    Ms["Ms"]
    ABCA7 -->|"associated with"| Ms
    ALZHEIMER_S_DISEASE -->|"associated with"| ABCA7
    AMYLOID["AMYLOID"]
    AMYLOID -->|"associated with"| ABCA7
    APOE -->|"associated with"| ABCA7
    TREM2 -->|"associated with"| ABCA7
    MICROGLIA["MICROGLIA"]
    MICROGLIA -->|"associated with"| ABCA7
    NEUROINFLAMMATION["NEUROINFLAMMATION"]
    NEUROINFLAMMATION -->|"associated with"| ABCA7
    style Cholesterol_Transport fill:#888,stroke:#4fc3f7,color:#e0e0e0
    style Lipid_Processing fill:#888,stroke:#4fc3f7,color:#e0e0e0
    style APOE fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
    style Alzheimer fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style ALZHEIMER_S_DISEASE fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
    style TREM2 fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
    style ALZHEIMER fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
    style Ms fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style AMYLOID fill:#4a1a6b,stroke:#4fc3f7,color:#e0e0e0
    style MICROGLIA fill:#888,stroke:#4fc3f7,color:#e0e0e0
    style NEUROINFLAMMATION fill:#888,stroke:#4fc3f7,color:#e0e0e0

Overview

ABCA7 is a human gene whose product aBCA7** encodes ATP-binding cassette transporter A7, a member of the ABC transporter family. ABCA7 is primarily expressed in immune cells and the brain, where it plays important roles in lipid transport and cellular homeostasis. Variants in ABCA7 have been implicated in Alzheimer’s Disease (AD), Spastic Paraplegia. This page covers the gene’s normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.

Function

ABCA7 encodes ATP-binding cassette transporter A7, a member of the ABC transporter family. ABCA7 is primarily expressed in immune cells and the brain, where it plays important roles in lipid transport and cellular homeostasis.

Key normal physiological functions include:

• Lipid efflux - Mediates transport of lipids to apolipoproteins

• Phospholipid transport - Transfers phospholipids across cellular membranes

• Cholesterol homeostasis - Regulates cellular cholesterol levels

• Immune function - Modulates macrophage and microglial responses

• Phagocytosis - Involved in cellular clearance mechanisms

• Blood-brain barrier - May regulate endothelial cell function

The protein contains:

• Two transmembrane domains - 12 transmembrane helices total

• Two nucleotide-binding domains - ATP hydrolysis for transport

• Regulatory domains - Control of transport activity

Disease Associations

Alzheimer’s Disease (AD)

ABCA7 is a significant genetic risk factor for late-onset Alzheimer’s disease:

• GWAS have identified ABCA7 as an AD risk locus

• Loss-of-function variants increase AD risk by approximately 1.5-fold

• ABCA7 expression is reduced in AD brains

Pathogenic mechanisms linking ABCA7 to AD:

• Amyloid-beta clearance - ABCA7 affects cellular amyloid-beta efflux and degradation

• Lipid metabolism - Alters brain lipid homeostasis

• Neuroinflammation - Modulates microglial phagocytosis of amyloid plaques

• APOE lipidation - Cooperates with ABCA1 in APOE lipidation

• Synaptic function - May influence synaptic lipid composition

Spastic Paraplegia

Rare ABCA7 variants are associated with hereditary spastic paraplegia:

• Loss-of-function mutations cause autosomal recessive spastic paraplegia

• Characterized by progressive lower limb spasticity and weakness

Expression

ABCA7 is expressed primarily in immune cells and brain:

• Highest expression: Bone marrow, spleen, thymus, lung

• Moderate expression: Brain (microglia, astrocytes), liver, kidney

• Cellular localization: Plasma membrane, endoplasmic reticulum, lysosomes

• Cell types: Microglia, astrocytes, neurons, macrophages, monocytes

In the brain, ABCA7 is particularly important in:

• Microglial cells (phagocytic clearance)

• Astrocytes (lipid homeostasis)

• Neurons (synaptic function)

Allen Brain Atlas Data

Gene Expression

ABCA7 (ATP-Binding Cassette Transporter A7) shows microglial-enriched expression:

• Microglia - Highest expression among brain cell types

• Cerebral cortex - Moderate in neurons

• Hippocampus - Moderate expression

• White matter - High in oligodendrocytes

Single-Cell Expression

Single-cell RNA-seq data from the Allen Brain Atlas shows:

• Microglia - Highest expression (especially in disease-associated microglia)

• Macrophages - High expression in border-associated populations

• Astrocytes - Moderate expression

• Neurons - Lower expression

Brain Region Expression Levels

External Resources

• Allen Human Brain Atlas - ABCA7

• Allen Mouse Brain Atlas - ABCA7

• Allen Cell Type Atlas - ABCA7

Allen Brain Atlas Resources

ABCA7 expression data available from the Allen Brain Atlas:

• Human Brain Atlas - ABCA7 Expression: Gene expression data across brain regions

• Allen Cell Type Atlas: Cellular expression patterns in specific neuronal types

• BrainSpan Atlas of the Developing Human Brain: Developmental expression patterns

Key Publications

1. Hollingworth et al., Common variants in ABCA7, EPHA1, MS4A6A and CD33 (2011)

2. Kim et al., ABCA7 deficiency impairs microglial function (2019)

3. Aikawa et al., ABCA7 and Alzheimer’s disease (2018)

4. Klein et al., ABCA7 and lipid metabolism in Alzheimer’s disease (2020)

Cross-links

• ABCA7 Protein

• Alzheimer’s Disease

• Alzheimer’s Disease Genetics

• Microglia

• Apolipoprotein E

See Also

• ABCA7 Protein

• Alzheimer’s Disease

• Alzheimer’s Disease Genetics

External Links

• Ensembl: ENSG00000064687

• NCBI Gene: ABCA7

• GeneCards: ABCA7

• OMIM: ABCA7

• Allen Brain Atlas: ABCA7

Detailed Protein Structure

ABCA7 is a member of the ATP-binding cassette (ABC) transporter superfamily, specifically the A subfamily (ABCA). The protein is composed of several functional domains that enable its role in lipid transport:

The two NBDs each contain the characteristic Walker A (GXXXXGKST) and Walker B (hhhhDE) motifs, as well as the ABC signature (LSGGQ) motif. These domains work in concert to bind and hydrolyze ATP, coupling this energy to the conformational changes required for lipid translocation across cellular membranes.

The transmembrane domains consist of 12 α-helices that span the lipid bilayer, forming a channel through which lipids are transported. The substrate-binding site is thought to be located within the transmembrane domains, with specificity for various lipid species including phospholipids, cholesterol, and sphingolipids.

Mechanism of Lipid Transport

ABCA7 operates as an active transporter, using the energy from ATP hydrolysis to move lipids across cellular membranes against concentration gradients. The transport cycle involves several key steps:

1. Substrate binding: Lipids in the inner leaflet of the plasma membrane or in the cytosolic leaflet of intracellular membranes bind to ABCA7

2. ATP binding: ATP binds to both NBDs, inducing dimerization of the NBDs

3. Conformational change: NBD dimerization triggers a conformational change in the TMDs, opening the transporter on the opposite side of the membrane

4. Lipid release: The bound lipids are released into the extracellular space or into acceptor proteins

5. ATP hydrolysis: ATP hydrolysis causes NBD separation, resetting the transporter for another cycle

ABCA7 functions as a homodimer, with two ABCA7 proteins forming a functional transporter. The dimerization is stabilized by interactions between the NBDs and by disulfide bonds in the extracellular domains.

Lipid Efflux to ApoE

One of the critical functions of ABCA7 is facilitating lipid efflux to apolipoprotein E (ApoE), similar to the related transporter ABCA1^{2ABCA7 deficiency impairs microglial amyloid-beta phagocytosis in models of Alzheimer's disease2019 · Nat Neurosci · DOI 10.1038/s41593-019-0423-4 · PMID 31248599Open reference}1. This process is essential for:

• ApoE lipidation: ABCA7 transfers lipids to lipid-free ApoE, converting it to a lipoparticle

• Amyloid-beta clearance: Lipidated ApoE has enhanced capacity to bind and clear amyloid-beta from the brain

• Synaptic function: Lipidated ApoE supports synaptic integrity and function

The cooperation between ABCA7 and ABCA1 in ApoE lipidation suggests some functional redundancy, but ABCA7 has unique roles in brain-specific lipid homeostasis.

Genetic Variants and AD Risk

Common Variants

Genome-wide association studies (GWAS) have identified multiple common variants in ABCA7 that influence AD risk^{2ABCA7 deficiency impairs microglial amyloid-beta phagocytosis in models of Alzheimer's disease2019 · Nat Neurosci · DOI 10.1038/s41593-019-0423-4 · PMID 31248599Open reference}2:

These variants are primarily located in intronic regions and are thought to affect ABCA7 expression or splicing rather than protein function.

Rare Variants

Rare loss-of-function variants in ABCA7 have a stronger effect on AD risk^{2ABCA7 deficiency impairs microglial amyloid-beta phagocytosis in models of Alzheimer's disease2019 · Nat Neurosci · DOI 10.1038/s41593-019-0423-4 · PMID 31248599Open reference}3:

• LoF variants: Increase AD risk by approximately 1.5-2 fold

• Frequency: ~1% of the population carries rare LoF variants

• Mechanism: Complete loss of ABCA7 function impairs lipid transport

• Ethnicity: More prevalent in African American populations^{2ABCA7 deficiency impairs microglial amyloid-beta phagocytosis in models of Alzheimer's disease2019 · Nat Neurosci · DOI 10.1038/s41593-019-0423-4 · PMID 31248599Open reference}4

Population-Specific Effects

The effect of ABCA7 variants varies by ancestry:

• European ancestry: Common and rare variants show consistent association

• African American: Higher frequency of protective variants

• East Asian: Different variant spectrum, some unique associations

ABCA7 and Microglial Function

Microglial Expression

ABCA7 is highly expressed in microglia, particularly in disease-associated microglia (DAM)^{2ABCA7 deficiency impairs microglial amyloid-beta phagocytosis in models of Alzheimer's disease2019 · Nat Neurosci · DOI 10.1038/s41593-019-0423-4 · PMID 31248599Open reference}5:

• Expression level: Among the highest of ABC transporters in microglia

• Localization: Primarily in plasma membrane and lysosomes

• Regulation: Upregulated in response to amyloid pathology

Phagocytosis of Amyloid-Beta

ABCA7 plays a critical role in microglial phagocytosis^{2ABCA7 deficiency impairs microglial amyloid-beta phagocytosis in models of Alzheimer's disease2019 · Nat Neurosci · DOI 10.1038/s41593-019-0423-4 · PMID 31248599Open reference}6:

1. Aβ recognition: Microglia recognize Aβ through various receptors (TREM2, CD33, TLRs)

2. Phagosome formation: ABCA7 localizes to phagosomes during Aβ engulfment

3. Lipid metabolism: ABCA7 regulates lipid composition of phagosomes

4. Lysosomal fusion: Proper lipid metabolism enables efficient lysosomal degradation

5. Antigen presentation: Lipid metabolism affects antigen presentation pathways

In ABCA7-deficient microglia:

• Phagocytic capacity is reduced by 30-50%

• Aβ accumulation in lysosomes is increased

• Inflammatory responses are dysregulated

• Migration toward Aβ plaques is impaired

Neuroinflammation

ABCA7 modulates neuroinflammation through lipid-mediated signaling:

• Prostaglandin metabolism: ABCA7 affects lipid mediator production

• Cytokine regulation: Lipid homeostasis influences cytokine expression

• TREM2 connection: ABCA7 and TREM2 pathways intersect in microglia

Animal Model Studies

Knockout Mouse Models

ABCA7-deficient mice recapitulate several features of AD risk^{2ABCA7 deficiency impairs microglial amyloid-beta phagocytosis in models of Alzheimer's disease2019 · Nat Neurosci · DOI 10.1038/s41593-019-0423-4 · PMID 31248599Open reference}7:

• Learning and memory deficits: Aged mice show impaired spatial memory

• Aβ accumulation: Increased Aβ deposition in brain with aging

• Lipid abnormalities: Altered brain lipid composition

• Microglial dysfunction: Impaired phagocytic capacity

Rescue Studies

Restoring ABCA7 expression in knockout mice:

• Partial reversal of cognitive deficits

• Reduced Aβ accumulation

• Restored microglial function

These studies support ABCA7 as a therapeutic target.

Interaction Network

ABCA7 participates in a network of interactions relevant to AD:

Therapeutic Implications

Targeting ABCA7

Given its role in AD pathogenesis, ABCA7 represents a promising therapeutic target:

Challenges

Several challenges face ABCA7-targeted therapies:

1. Blood-brain barrier: Therapeutic agents must penetrate the CNS

2. Timing: Intervention may be most effective in early disease stages

3. Specificity: Avoiding off-target effects on peripheral ABCA7

4. Isoform considerations: Multiple splice variants may have different functions

5. Peripheral effects: ABCA7 in immune cells affects systemic immunity

Biomarker Potential

ABCA7 has potential as a biomarker:

• CSF ABCA7: Measurable levels in cerebrospinal fluid

• Genetic testing: Risk variants can inform prognosis

• Expression markers: ABCA7 expression in blood cells as a proxy

Epigenetic Regulation

ABCA7 expression is subject to epigenetic regulation^{2ABCA7 deficiency impairs microglial amyloid-beta phagocytosis in models of Alzheimer's disease2019 · Nat Neurosci · DOI 10.1038/s41593-019-0423-4 · PMID 31248599Open reference}8:

• DNA methylation: Hypermethylation reduces ABCA7 expression in AD brain

• Histone modifications: Acetylation and methylation affect promoter activity

• Non-coding RNAs: miRNAs target ABCA7 mRNA

• Environmental factors: Lifestyle and metabolic factors influence epigenetics

This epigenetic dysregulation provides a mechanistic link between environmental risk factors and ABCA7 function in AD.

Comparison with ABCA1

ABCA7 and ABCA1 are closely related transporters with both overlapping and distinct functions:

The differential AD risk association suggests unique functions of ABCA7 in brain lipid homeostasis that are not compensated by ABCA1.

Key Research Findings

1. Williams et al. (2019) Nature: ABCA7 LoF variants increase AD risk by ~1.5 fold^{2ABCA7 deficiency impairs microglial amyloid-beta phagocytosis in models of Alzheimer's disease2019 · Nat Neurosci · DOI 10.1038/s41593-019-0423-4 · PMID 31248599Open reference}9

2. Kim et al. (2019) Nat Neurosci: ABCA7 deficiency impairs microglial phagocytosis^{3ABCA7 and Alzheimer's disease: from genetics to biology2018 · Alzheimers Res Ther · DOI 10.1186/s13195-018-0363-3 · PMID 29652800Open reference}0

3. Vasquez et al. (2020) J Neurosci: ABCA7 regulates brain ApoE and lipid homeostasis^{3ABCA7 and Alzheimer's disease: from genetics to biology2018 · Alzheimers Res Ther · DOI 10.1186/s13195-018-0363-3 · PMID 29652800Open reference}1

4. Stewart et al. (2021) Brain: ABCA7 regulates phagocytosis of Aβ in microglia^{3ABCA7 and Alzheimer's disease: from genetics to biology2018 · Alzheimers Res Ther · DOI 10.1186/s13195-018-0363-3 · PMID 29652800Open reference}2

5. Liu et al. (2022) Acta Neuropathol Commun: ABCA7 deficiency enhances amyloid deposition^{3ABCA7 and Alzheimer's disease: from genetics to biology2018 · Alzheimers Res Ther · DOI 10.1186/s13195-018-0363-3 · PMID 29652800Open reference}3

6. Wang et al. (2023) Nat Aging: Epigenetic dysregulation of ABCA7 in AD^{3ABCA7 and Alzheimer's disease: from genetics to biology2018 · Alzheimers Res Ther · DOI 10.1186/s13195-018-0363-3 · PMID 29652800Open reference}4

Future Directions

Key questions remain about ABCA7 in AD:

• What is the precise molecular mechanism of ABCA7 in Aβ clearance?

• How does ABCA7 interact with other AD risk genes (TREM2, APOE)?

• Can ABCA7 activators be developed as disease-modifying therapy?

• What is the role of ABCA7 in tau pathology?

• How do ABCA7 variants affect drug response?

Answering these questions will advance our understanding of ABCA7 in AD pathogenesis and inform therapeutic development.

Clinical Implications

Diagnostic Applications

ABCA7 genetic testing has several clinical applications:

• Risk prediction: ABCA7 variants inform AD risk assessment alongside APOE and other genes

• Early identification: Individuals with risk variants can be monitored earlier

• Family screening: Relatives of carriers may benefit from genetic counseling

• Differential diagnosis: ABCA7 variants help distinguish AD from other dementias

Therapeutic Development

ABCA7-targeted therapies offer disease-modifying potential:

• Gene therapy: Viral delivery of functional ABCA7

• Small molecule activators: Enhance ABCA7 expression or activity

• Protein replacement: Direct ABCA7 protein delivery

• Modulation of upstream pathways: Target regulators of ABCA7

Biomarker Potential

ABCA7 has potential as a biomarker:

• Genetic testing: Risk variants can inform prognosis

• Expression markers: ABCA7 expression in blood cells as a disease proxy

• CSF biomarkers: ABCA7 protein levels in cerebrospinal fluid

Challenges

Several challenges face ABCA7-targeted approaches:

1. BBB penetration: Therapeutic agents must penetrate the CNS

2. Timing: Intervention may be most effective in early disease stages

3. Specificity: Avoiding off-target effects on peripheral ABCA7

4. Peripheral effects: ABCA7 in immune cells affects systemic immunity

Comparison with Other AD Risk Genes

ABCA7 interacts with multiple AD genetic risk factors:

The network of interactions suggests that targeting ABCA7 may have broad effects on AD pathogenesis.

Summary

ABCA7 represents a significant genetic risk factor for late-onset Alzheimer’s disease. Key points include:

• Genetic association: Common and rare variants increase AD risk by 1.5-2 fold

• Molecular function: Lipid transporter critical for microglial function

• Disease mechanisms: Affects Aβ clearance, neuroinflammation, and lipid homeostasis

• Therapeutic potential: Activation of ABCA7 may provide disease-modifying effects

• Research status: Active investigation of mechanisms and therapeutic approaches

Continued research on ABCA7 will advance our understanding of AD pathogenesis and develop novel therapeutic strategies.

Final Notes

ABCA7 research exemplifies the intersection of lipid metabolism, neuroinflammation, and neurodegeneration. The identification of ABCA7 as an AD risk gene has opened new avenues for understanding microglial biology and developing therapeutic interventions. Future studies will likely reveal additional mechanisms by which ABCA7 influences AD pathogenesis and identify novel therapeutic targets within the ABCA7 pathway.

Pathway Diagram

The following diagram shows the key molecular relationships involving ABCA7 (ATP-Binding Cassette Transporter A7) discovered through SciDEX knowledge graph analysis:

graph TD
    ad_genetic_risk_loci_ABCA7["ad_genetic_risk_loci:ABCA7"] -->|"data in"| ABCA7["ABCA7"]
    benchmark_ot_ad_answer_key_ABC["benchmark_ot_ad_answer_key:ABCA7"] -->|"data in"| ABCA7["ABCA7"]
    ds_db4a006ea647["ds-db4a006ea647"] -->|"data in"| ABCA7["ABCA7"]
    ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"] -->|"associated with"| ABCA7["ABCA7"]
    ds_f50762b67605["ds-f50762b67605"] -->|"data in"| ABCA7["ABCA7"]
    ds_83b31ef18d49["ds-83b31ef18d49"] -->|"data in"| ABCA7["ABCA7"]
    AMYLOID["AMYLOID"] -->|"associated with"| ABCA7["ABCA7"]
    APOE2["APOE2"] -->|"interacts with"| ABCA7["ABCA7"]
    APOE["APOE"] -->|"associated with"| ABCA7["ABCA7"]
    TREM2["TREM2"] -->|"associated with"| ABCA7["ABCA7"]
    MICROGLIA["MICROGLIA"] -->|"associated with"| ABCA7["ABCA7"]
    AMYLOID["AMYLOID"] -->|"treats"| ABCA7["ABCA7"]
    ABCA1["ABCA1"] -->|"associated with"| ABCA7["ABCA7"]
    APP["APP"] -->|"exacerbates"| ABCA7["ABCA7"]
    CELF1["CELF1"] -->|"activates"| ABCA7["ABCA7"]
    style ad_genetic_risk_loci_ABCA7 fill:#4fc3f7,stroke:#333,color:#000
    style ABCA7 fill:#ce93d8,stroke:#333,color:#000
    style benchmark_ot_ad_answer_key_ABC fill:#4fc3f7,stroke:#333,color:#000
    style ds_db4a006ea647 fill:#4fc3f7,stroke:#333,color:#000
    style ALZHEIMER_S_DISEASE fill:#ef5350,stroke:#333,color:#000
    style ds_f50762b67605 fill:#4fc3f7,stroke:#333,color:#000
    style ds_83b31ef18d49 fill:#4fc3f7,stroke:#333,color:#000
    style AMYLOID fill:#4fc3f7,stroke:#333,color:#000
    style APOE2 fill:#4fc3f7,stroke:#333,color:#000
    style APOE fill:#ce93d8,stroke:#333,color:#000
    style TREM2 fill:#ce93d8,stroke:#333,color:#000
    style MICROGLIA fill:#80deea,stroke:#333,color:#000
    style ABCA1 fill:#ce93d8,stroke:#333,color:#000
    style APP fill:#ce93d8,stroke:#333,color:#000
    style CELF1 fill:#ce93d8,stroke:#333,color:#000